^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mucosal Melanoma |
| Drug: | nemvaleukin alfa (ALKS 4230) (IL-2R agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Published date:
08/02/2021
Excerpt:
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, for the treatment of mucosal melanoma.
